All Stories

  1. Outcomes of acute pertioneal dialysis in COVID-19 patients
  2. An aspirational diet for dialysis patients: Evidence and theory
  3. Usefulness of Dietary Components as Sustainable Nutraceuticals for Chronic Kidney Disease
  4. Dietary Phosphorus: Health, Nutrition, and Regulatory Aspects
  5. Phosphorus in the Modern Food Supply: Underestimation of Exposure
  6. Molecular Mechanisms of Adverse Health Effects Associated With Excess Phosphorus Intake
  7. Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
  8. Intake of high fructose corn syrup sweetened soft drinks is associated with prevalent chronic bronchitis in U.S. Adults, ages 20–55 y
  9. Dietary Advanced Glycation End Products and Their Role in Health and Disease
  10. Levels of advanced glycation end products (AGEs), AGE's receptor (sRAGE) and their relationship with cardiovascular risk factors in newly diagnosed type 2 diabetic patients
  11. The Low AGE Diet: A Neglected Aspect of Clinical Nephrology Practice?
  12. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men
  13. Advanced glycation end product accumulation
  14. Dietary Protein and Fiber in End Stage Renal Disease
  15. Dietary advanced glycation end products are associated with decline in memory in young elderly
  16. What Can We Learn from the Saga of Chitosan Gums in Hyperphosphatemia Therapy?
  17. Increased circulating advanced glycation endproducts (AGEs) in acute trauma patients
  18. Processing Contaminants: Advanced Glycation End Products (AGEs)
  19. Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?
  20. Introduction toDietary Phosphorus Excess and Health
  21. Potassium Balance in Dialysis Patients
  22. Dietary phosphorus and kidney disease
  23. Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases
  24. Contributions to Total Phosphorus Intake: All Sources Considered
  25. A Practical Approach to Acid-Base Disturbances
  26. Role of Advanced Glycation Endproducts and Potential Therapeutic Interventions in Dialysis Patients
  27. Phosphorus-containing food additives: An insidious danger for people with chronic kidney disease
  28. Effects of Sevelamer on HbA1c, Inflammation, and Advanced Glycation End Products in Diabetic Kidney Disease
  29. The key to halting progression of CKD might be in the produce market, not in the pharmacy
  30. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals
  31. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals
  32. Treatment of secondary hyperparathyroidism in chronic kidney disease, and its effect on the QT interval
  33. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging
  34. Identifying Advanced Glycation End Products as a Major Source of Oxidants in Aging: Implications for the Management and/or Prevention of Reduced Renal Function in Elderly Persons
  35. Metabolic abnormalities are present in adults with elevated serum cystatin C
  36. Hereditary Nephrogenic Diabetes insipidus and Bilateral Nonobstructive Hydronephrosis
  37. Renal Hypouricemia and Absorptive Hypercalciuria: A Real Syndrome
  38. Mechanism of Normochloremic and Hyperchloremic Acidosis in Diabetic Ketoacidosis
  39. Bartter’s Syndrome Due to a Defect in Salt Reabsorption in the Distal Convoluted Tubule
  40. Pseudohypoaldosteronism following Kidney Transplantation
  41. Weight Increase Is Associated with Skeletal Muscle Immunostaining for Advanced Glycation End Products, Receptor for Advanced Glycation End Products, and Oxidation Injury
  42. Editorial: Diet, Inflammation, and Chronic Kidney Disease: Getting to the Heart of the Matter
  43. Advanced Glycation End Product Homeostasis
  44. Overweight, Obesity, and Elevated Serum Cystatin C Levels in Adults in the United States
  45. Dietary Advanced Glycation Endproducts and Oxidative Stress
  46. Opinion: How Should Dialysis Fluid Be Individualized for the Chronic Hemodialysis Patient?
  47. Acid-Base Balance in Dialysis Patients: A Reassessment
  48. PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphorus Homeostasis in Normal Health and in Chronic Kidney Disease Patients with Special Emphasis on Dietary Phosphorus Intake
  49. Cerebrovascular effects of hemodialysis in chronic kidney disease
  50. NORMAL HOMOCYSTEINE LEVELS IN WELL-FUNCTIONING OLDEST-OLD INDIVIDUALS DESPITE LOW KIDNEY FUNCTION
  51. Association of Advanced Glycoxidation End Products and Inflammation Markers with Thrombosis of Arteriovenous Grafts in Hemodialysis Patients
  52. Hidden Phosphorus-Enhanced Meats: Part 3
  53. Oral phosphate binders in the treatment of pseudoxanthoma elasticum
  54. Correspondence: Cinacalcet Cost and Utility in Dialysis Patients
  55. Diet-Derived Advanced Glycation End Products Are Major Contributors to the Body's AGE Pool and Induce Inflammation in Healthy Subjects
  56. Diabetes and Advanced Glycoxidation End-Products
  57. Opinion: What Unique Acid-Base Considerations Exist in Dialysis Patients?
  58. K/DOQI Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Patients: Some Therapeutic Implications
  59. Glycoxidation and Diabetic Complications: Modern Lessons and a Warning?
  60. Advanced glycoxidation end products in commonly consumed foods
  61. Glycoxidation and inflammation in renal failure patients
  62. The role of advanced glycation end products in the development of atherosclerosis
  63. Effect of Exercise on the Diameter of Arteriovenous Fistulae in Hemodialysis Patients
  64. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients
  65. In reply
  66. Hidden Sources of Phosphorus in the Typical American Diet: Does it Matter in Nephrology?
  67. Venous access: Women are equal
  68. Hyperphosphatemia Management
  69. Dialysis Clinic: Unrecognized Sources of Dietary Phosphate
  70. Relation between Interdialytic Weight Gain, Body Weight and Nutrition in Hemodialysis Patients
  71. Dialysis Patient Characteristics and Outcomes
  72. Advanced Glycoxidation: A New Risk Factor for Cardiovascular Disease?
  73. Impact of the Surgeon on the Prevalence of Arteriovenous Fistulas
  74. ACID-BASE IN RENAL FAILURE: Introduction
  75. ACID-BASE IN RENAL FAILURE: Concluding Remarks
  76. ACID-BASE IN RENAL FAILURE: Acidosis in Chronic Renal Insufficiency
  77. Reteplase in the Treatment of Thrombosed Hemodialysis Grafts
  78. Gender modulates responsiveness to recombinant erythropoietin
  79. Hemodialysis access placement with preoperative noninvasive vascular mapping: Comparison between patients with and without diabetes
  80. DOQI guidelines for nutrition in long-term peritoneal dialysis patients: A dissenting view
  81. Management of hemodialysis patients with central venous stenoses or occlusions
  82. Thrombolysis of Clotted Hemodialysis Grafts with Tissue-type Plasminogen Activator
  83. Adequacy of dialysis and differences in hematocrit among dialysis facilities
  84. Relationship between phosphorus and creatinine clearance in peritoneal dialysis: Clinical implications
  85. Marked hyperlactatemia associated with severe alkalemia in a patient with thrombotic thrombocytopenic purpura
  86. Mild Metabolic Acidosis and Protein Metabolism in Dialysis Patients: A Reasoned Approach to Alkali Therapy
  87. Carboxyhemoglobin and Lactate Levels Do Not Correlate in Critically III Patients
  88. Association of acidosis and nutritional parameters in hemodialysis patients
  89. Protein Intake Seems to Respond to Increases in Kt/V despite Baseline Kt/V Greater than 1.2
  90. Protein Catabolic Rate May Underestimate Dietary Protein Intake in Hemodialysis Patients
  91. In Reply
  92. Recurrence of scleroderma in a renal allograft from an identical twin sister
  93. D-Lactic Acidosis: A Review of Clinical Presentation, Biochemical Features, and Pathophysiologic Mechanisms
  94. A re-evaluation of the urinary parameters of acid production and excretion in patients with chronic renal acidosis
  95. Acid-base balance in chronic peritoneal dialysis patients
  96. Renal Stone Risk Factors in Patients With Type IV Renal Tubular Acidosis
  97. The Reply
  98. The reply
  99. Altered water metabolism in tuberculosis: Role of vasopressin
  100. Hyperkalemia in diabetes mellitus
  101. Metabolic Acidosis due to Inapparent Defects in Renal Acid Excretion in a Patient with Chronic Diarrhea
  102. Prevention of Myelinolysis in Rats by Dexamethasone or Colchicine
  103. The First Kidney Stone
  104. Electrolyte Case Vignette: A Case of Unusual Organic Acidosis Man
  105. Metabolic utilization and renal handling of d-lactate in men
  106. A Mechanism of Hypoxemia during Hemodialysis
  107. Salt-Losing Nephropathy